[go: up one dir, main page]

AU2001270637A1 - Multi-specific reagent for selective stimulation of cell surface receptors - Google Patents

Multi-specific reagent for selective stimulation of cell surface receptors

Info

Publication number
AU2001270637A1
AU2001270637A1 AU2001270637A AU7063701A AU2001270637A1 AU 2001270637 A1 AU2001270637 A1 AU 2001270637A1 AU 2001270637 A AU2001270637 A AU 2001270637A AU 7063701 A AU7063701 A AU 7063701A AU 2001270637 A1 AU2001270637 A1 AU 2001270637A1
Authority
AU
Australia
Prior art keywords
cell surface
surface receptors
specific reagent
selective stimulation
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270637A
Inventor
Gundram Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001270637A1 publication Critical patent/AU2001270637A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A multispecific reagent has at least one first binding site for a cell surface receptor which requires multimeric ligand binding to be stimulated. The reagent possesses a second binding site for a target antigen which is expressed on the same cell as the cell surface receptor.
AU2001270637A 2000-07-20 2001-07-14 Multi-specific reagent for selective stimulation of cell surface receptors Abandoned AU2001270637A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10034607A DE10034607A1 (en) 2000-07-20 2000-07-20 Multi-specific reagent for the selective stimulation of cell surface receptors
DE10034607 2000-07-20
PCT/EP2001/008147 WO2002008291A2 (en) 2000-07-20 2001-07-14 Multi-specific reagent for selective stimulation of cell surface receptors

Publications (1)

Publication Number Publication Date
AU2001270637A1 true AU2001270637A1 (en) 2002-02-05

Family

ID=7649143

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001270637A Abandoned AU2001270637A1 (en) 2000-07-20 2001-07-14 Multi-specific reagent for selective stimulation of cell surface receptors

Country Status (10)

Country Link
US (1) US8058399B2 (en)
EP (1) EP1303540B1 (en)
JP (1) JP4866532B2 (en)
AT (1) ATE315585T1 (en)
AU (1) AU2001270637A1 (en)
CA (1) CA2416572C (en)
DE (2) DE10034607A1 (en)
ES (1) ES2256269T3 (en)
PT (1) PT1303540E (en)
WO (1) WO2002008291A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
ES2871905T3 (en) 2002-03-01 2021-11-02 Immunomedics Inc Immunoconjugate comprising humanized RS7 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
JP4818917B2 (en) * 2003-08-08 2011-11-16 イミューノメディクス、インコーポレイテッド Bispecific antibodies for inducing apoptosis of tumors and diseased cells
EP1756162A1 (en) * 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
PT3056515T (en) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Methods for manipulating phagocytosis mediated by cd47
PT4160212T (en) 2008-01-15 2024-06-25 Univ Leland Stanford Junior Markers of acute myeloid leukemia stem cells
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
RU2492871C2 (en) * 2008-08-01 2013-09-20 АКСИС, Инс. Therapeutic or preventive drug for treating osteoarthritis
KR101508043B1 (en) * 2009-09-29 2015-04-06 로슈 글리카트 아게 Bispecific death receptor agonistic antibodies
LT2647707T (en) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9624310B2 (en) 2011-11-17 2017-04-18 Gundram Jung Methods of using bi-specific antibodies for treating B-cell-mediated autoimmune diseases or auto-reactive B-cells
SG11201405468QA (en) 2012-03-14 2014-10-30 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
CA2891764A1 (en) * 2012-11-19 2014-05-22 Baliopharm Ag Recombinant bispecific antibody binding to cd20 and cd95
UA118028C2 (en) 2013-04-03 2018-11-12 Рош Глікарт Аг Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
MX380176B (en) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd IMMUNOACTIVATED ANTIGEN-BOUND MOLECULE.
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
KR20180025865A (en) 2015-07-06 2018-03-09 리제너론 파마슈티칼스 인코포레이티드 Multispecific antigen binding molecules and uses thereof
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
JP6931329B2 (en) 2015-11-18 2021-09-01 中外製薬株式会社 Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
CN110809583A (en) 2017-06-07 2020-02-18 瑞泽恩制药公司 Compositions and methods for internalizing enzymes
JP7328990B2 (en) 2018-04-30 2023-08-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Antibodies and bispecific antigen binding molecules that bind to HER2 and/or APLP2, and conjugates and uses thereof
MX2020012350A (en) 2018-05-17 2021-01-29 Regeneron Pharma ANTI-CD63 ANTIBODIES, CONJUGATED AND THEIR USES.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI105320B (en) * 1988-04-04 2000-07-31 Oncogen Procedure for Preparation of Antibody Heteroconjugates for Use in Regulating Lymphocyte Activity and Diagnosis
US6010902A (en) * 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5891434A (en) * 1991-06-17 1999-04-06 Centocor, Inc. Monoclonal antibodies to the APO-1 antigen
IL108776A (en) 1993-03-11 1999-11-30 Genentech Inc Method for cell lysis or inhibition of cell growth a bispecific molecule binding tnf-r1 and fas antigen a pharmaceutical composition containing it and its use
DE19531849A1 (en) 1994-08-31 1996-03-07 Henkel Kgaa Polystyrene binders, used in adhesives, coatings and sealants,
DE19531348A1 (en) 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Antibodies with two or more specificities for the selective elimination of cells in vivo
WO1997012632A1 (en) * 1995-10-05 1997-04-10 Tkb Associates Limited Partnership Methods for treatment of diseases associated with a deficiency of fas ligand activity
EP0912612B1 (en) 1996-07-25 2003-10-01 GSF - Forschungszentrum für Umwelt und Gesundheit, GmbH Simplified production of bispecific antibody fragments
WO1998020896A1 (en) * 1996-11-15 1998-05-22 Health Research Inc. A method for inducing apoptosis of primary central nervous system b cell lymphomas
AU765003B2 (en) * 1998-03-27 2003-09-04 Genentech Inc. Apo-2 ligand-anti-her-2 antibody synergism
AU1727500A (en) * 1998-11-17 2000-06-05 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy

Also Published As

Publication number Publication date
US20030232049A1 (en) 2003-12-18
JP2004504408A (en) 2004-02-12
CA2416572C (en) 2011-04-26
DE50108680D1 (en) 2006-04-06
ES2256269T3 (en) 2006-07-16
US8058399B2 (en) 2011-11-15
EP1303540B1 (en) 2006-01-11
WO2002008291A2 (en) 2002-01-31
PT1303540E (en) 2006-05-31
DE10034607A1 (en) 2002-02-07
WO2002008291A3 (en) 2002-06-20
ATE315585T1 (en) 2006-02-15
CA2416572A1 (en) 2002-01-31
JP4866532B2 (en) 2012-02-01
EP1303540A2 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
AU2001270637A1 (en) Multi-specific reagent for selective stimulation of cell surface receptors
WO2002097059A3 (en) Chromosome-based platforms
GB2459412A (en) Device for leveling and aligning tiles and method for leveling and aligning tiles
WO2004096144A3 (en) Compositions and methods for induction of opioid receptors
AU2002952043A0 (en) Methods for making composite tiles
TW200630107A (en) Antibodies to OPGL
WO2003050295A3 (en) Assays and implements for determining and modulating hsp90 binding activity
AU2002312471A1 (en) Method for distributing large files to multiple recipients
TW200620664A (en) Semicomductor device and method for manufacturing the same
AU2002334658A1 (en) Fuel additives for fuel cell
PT1771630E (en) Fitting or slipping system for laying wooden floors on the outside and the inside
AU2003201826A8 (en) Compounds for delivering substances into cells
AU2003235687A1 (en) Histamine-3 receptor ligands for diabetic conditions
AU2003292759A1 (en) Fuel feed pump
WO2004022706A3 (en) Immune cell receptor ligand and immune cell receptor
PL366415A1 (en) Inhibition of the growth factor dependency of tumor cells
ATE390427T1 (en) DIAZABICYLONONAN AND DECAN DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS
AU2002212472A1 (en) Epitope-beta microglobulin polynucleotide for anti-cancer immunotherapy
AU2003303778A1 (en) Roof structure for greenhouses
AU2003212865A1 (en) Land mine probe
HK1044583A1 (en) Multi-purpose underground utility conduit system
WO2002096945A3 (en) Macrophage receptor agonist or antagonist
GB0216424D0 (en) Advanced fuel cell construction technique
AU2002351993A1 (en) Devices for supplying fuel to fuel cells
AU2003286245A1 (en) Silicon compounds to be used as ligands for retinoid receptors